Ongoing Research

1. A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (TIMI – 52 SOLID)

   It is understood that part the development of heart disease is an inflammatory process inside the blood vessels. This study analyzes the effect of a drug that reduces a known inflammatory substance in patients who are already at high risk for having another heart attack or stroke.

2. ASTRONAUT—Six months efficacy and safety of Aliskiren therapy on top of standard therapy, on morbidity and mortality in patients with acute decompensated heart failure. The Astronaut study will record the effectiveness of an FDA approved drug (Aliskiren) in a "non-label" use—in patients with Congestive Heart Failure with a recent hospitalization to treat their symptoms.

3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes (TIMI-53 SAVOR)

   Good blood glucose control is imperative to reduce cardiovascular complications in diabetics. This very large, international study follows diabetic patients who are given an already FDA approved medication to determine if it will specifically reduce the number of heart attacks and strokes.

4. TOPCAT—Treatment of preserved cardiac function in heart failure with an aldosterone antagonist. This study on Heart Failure patients tests to see if a common, already FDA approved CHF drug (spironolactone), if given as an early first line treatment, will slow or alter the progression of the disease.

5. TRILOGY ACS Study—A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with unstable angina/non-ST-Elevation myocardial infarction (UA/NSTEMI) who are medically managed.

   This clinical study compares a commonly prescribed blood-thinning drug (Plavix) to a recently FDA approved blood-thinning drug (Prasugrel) in patients who have known heart disease and are being managed just with medications, rather than surgery.

6. A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects with Permanent Pacemakers (HESTIA)

   This clinical trial follows patients with pacemakers and a small amount of A-fib to determine if they do better with the addition of a new FDA approved medication called Dronedarone.